CytoNiche Biotech

CytoNiche Biotech Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from CytoNiche Biotech, Biotechnology company, 1 FUSIONOPOLIS LINK #06-06, NEXUS@ONE-NORTH, Singapore.

CytoNiche™ revolutionizes CGT manufacturing with 3D FloTrix™ technology, offering GMP-grade dissolvable microcarriers, serum-free media for MSCs, and GMP-compliant equipment to support expansion, harvesting, processing, and filling.

03/06/2026

Scalable manufacturing. Regulatory-ready tech. And policy shifts that matter.

We recently had the pleasure of speaking with Dr. Marialaura Madrigal, Research Director of Medistem Panama Inc., who shared her perspectives on the growing importance of scalable cell manufacturing, the value of regulatory-ready technologies, and the opportunities emerging across the global CGT landscape.

From her experience with our 3D TableTrix™ Microcarriers and her views on China's recent 818 & 828 policies, the conversation highlights how technological innovation and regulatory progress can work together to accelerate the development of advanced therapies.

Thank you, Dr. Madrigal, for sharing your valuable insights.


01/06/2026

High DecaGiga Cell Manufacturing Masterclass successfully concluded at CytoNiche’s Beijing Headquarters, bringing together participants internationally for an intensive programme focused on the future of scalable regenerative medicine manufacturing.

As Cell & Gene Therapy continues advancing toward industrial-scale production, manufacturing is becoming just as important as scientific discovery. The ability to produce living therapies consistently, safely, and at scale will play a defining role in the future of regenerative medicine.

Throughout the programme, participants explored:
🔹 Scalable 3D cell culture technologies
🔹 Automated and closed-system manufacturing workflows
🔹 Microcarrier-based expansion strategies
🔹 Exosome harvesting and cell processing technologies
🔹 Aseptic filling and integrated manufacturing systems

Through a combination of theoretical sessions, live demonstrations, and hands-on operational training, participants gained practical insights into the evolving industrial landscape of advanced therapy manufacturing.

As the industry continues transitioning toward automation, standardisation, and scalable GMP-oriented manufacturing, workforce readiness and technical expertise will become increasingly critical across the global CGT ecosystem.

Thank you to all participants, collaborators, and team members who contributed to the success of this masterclass.

29/05/2026

Regenerative medicine is no longer limited by biology alone — manufacturing is becoming just as important.

As the CGT industry moves toward commercialization, regulators are placing greater focus on:
🔹 Manufacturing consistency
🔹 Process reproducibility
🔹 Traceability
🔹 Scalability

This is one reason why automated 3D cell manufacturing systems are gaining increasing attention across the industry.

Compared to traditional 2D culture methods, 3D manufacturing platforms may offer better scalability, reduced manual intervention, improved contamination control, and stronger GMP compatibility.

In this video, we explore why manufacturing technology could become one of the key factors shaping the future of regenerative medicine.

📄 Read the full article here: https://en.cytoniche.com/notes_detail/21.html

Beyond innovation, progress is ultimately built on humanity, trust, and shared purpose.This Hari Raya Haji, CytoNiche ce...
27/05/2026

Beyond innovation, progress is ultimately built on humanity, trust, and shared purpose.

This Hari Raya Haji, CytoNiche celebrates the spirit of dedication, resilience, and compassion that continues to bring communities together across borders and industries.

As we continue advancing scalable cell manufacturing technologies for the future of healthcare, we remain grateful for the trust, partnerships, and collaborations that make innovation possible.

Wishing our colleagues, partners, and friends around the world a meaningful Hari Raya Haji filled with peace, reflection, and togetherness.

Selamat Hari Raya Haji from all of us at CytoNiche.

25/05/2026

China’s new dual-track regulatory framework could become one of the most important shifts in the global cell and gene therapy industry.

With the implementation of Decrees 818 and 828, manufacturing is no longer just an operational consideration — it is becoming a core regulatory requirement.

Companies must now decide much earlier:
Is the therapy designed for personalised clinical application, or scalable pharmaceutical manufacturing?

That decision will shape regulatory strategy, manufacturing systems, quality control, and commercialisation from the very beginning.

In this video, we break down what China’s new framework means for the future of regenerative medicine manufacturing.

📄 Read the full article here: https://en.cytoniche.com/notes_detail/21.html

22/05/2026

🧬 Regenerative medicine is entering a new era — and not just because of science.

Yes, CAR-T and CRISPR are breakthroughs. But the real challenge?
Manufacturing.

Cell therapies are living products. They need to be made consistently, safely, and at scale. That's why the industry is moving from traditional 2D culture to automated 3D systems.

Regulators now ask: Can you replicate it?

In this video, we explain what this shift means — and tease a major regulatory update from China coming in Video 2.

📄 Read the full article here: https://en.cytoniche.com/notes_detail/21.html

Regenerative medicine is rapidly evolving from experimental research into a highly regulated and industrialised therapeu...
20/05/2026

Regenerative medicine is rapidly evolving from experimental research into a highly regulated and industrialised therapeutic sector. As stem cell therapies, gene editing, and cellular immunotherapies continue to advance, scalable manufacturing, process reproducibility, and regulatory compliance are becoming increasingly critical for successful clinical translation.

This article explores the future of regenerative medicine manufacturing and the impact of China’s newly implemented dual-track regulatory framework under State Council Decrees 818 and 828 on the global Cell & Gene Therapy industry.

📄 Read the full article here: https://en.cytoniche.com/notes_detail/21.html

18/05/2026

From “babysitter-dependent” to self-sufficient — NK cell expansion has come a long way.

Traditional feeder cell systems have enabled impressive expansion, but challenges in safety, consistency, and scalability have driven the shift towards feeder-free approaches. Increasingly, precise cytokine control and advanced activation strategies are redefining how NK cells are manufactured.

In this video, a closer look is taken at how NK cells are “raised” — and how the field is evolving towards smarter, safer, and more scalable solutions.

📄 Read the full article here: en.cytoniche.com/notes_detail/20.html

Over the past few days, we’ve heard directly from many of you on the challenges of moving from manual processes to more ...
16/05/2026

Over the past few days, we’ve heard directly from many of you on the challenges of moving from manual processes to more automated, scalable systems — a transition that’s clearly top of mind across the field.

It’s been especially rewarding to see the interest in how the 3D FloTrix™ platform can support this shift, and how many were pleasantly surprised by its simplicity and adaptability within existing workflows.

A big thank you to everyone who stopped by Booth 1160 and shared your experiences with us — these conversations are what make events like ASGCT truly valuable. And of course, our thanks to ASGCT for organising such a successful and engaging event.

If we didn’t get the chance to connect, or if you’d like to continue the discussion, we’d love to stay in touch. You can also get a glimpse of our 3D FloTrix™ Platform here: https://en.cytoniche.com/

Till next time 👋

13/05/2026

Day 1 at ASGCT 2026 — we’re officially live in Boston📍 Booth 1160

It’s been a highly insightful first day at ASGCT 2026, with many teams consulting us on their current challenges — particularly around scaling workflows and reducing reliance on manual processes.

Across these discussions, a consistent theme has emerged: the need for solutions that not only improve efficiency, but also integrate smoothly into existing processes without adding unnecessary complexity. From early-stage development to pre-clinical and manufacturing considerations, teams are looking for practical ways to scale with confidence.

Come by, share what you’re working on, and let’s explore what’s possible together.

If we missed you today, there’s still more to come. We’ll be here over the next few days — feel free to drop by and continue the conversation.

Address

1 FUSIONOPOLIS LINK #06-06, NEXUS@ONE-NORTH
Singapore
138542

Opening Hours

Monday 09:00 - 18:00
Tuesday 09:00 - 18:00
Wednesday 09:00 - 18:00
Thursday 09:00 - 18:00
Friday 09:00 - 18:00

Website

Alerts

Be the first to know and let us send you an email when CytoNiche Biotech posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to CytoNiche Biotech:

Shortcuts

Share

Category